Alamar Biosciences presented extensive data from its NULISA platform at the AAIC 2026 conference, highlighting advances in blood-based biomarkers for Alzheimer's detection and staging. The company emphasized new findings on eMTBR-Tau and BD-pTau217, two highly specific blood markers, which improve disease differentiation and early detection when combined. Their multiplex protein profiling technology allows simultaneous measurement of tau pathology, neuroinflammation, and neurodegeneration markers, offering deeper insights into Alzheimer's progression. Alamar also hosted a workshop to discuss these innovations, signaling growing adoption of their technology in Alzheimer's research.
Institutional investors are favoring spot Bitcoin and Ethereum ETFs like BlackRock IBIT and Fidelity FBTC, driving steady inflows that support Bitcoin's price around $64,119 and Ethereum near $1,897. This trend highlights a preference for lower-fee, ...
The Monad Foundation's $60 million liquidity program, aimed at reducing selling pressure by allowing early investors to sell locked MON tokens at a discount, was largely rejected as most investors chose to hold their tokens. While this could suggest ...
Zcash (ZEC) has unexpectedly broken out of its recent consolidation, driven by a bullish golden EMA crossover around $495 while trading near $509. This technical signal suggests increased intermediate momentum, supported by strong long-term support l...
Long-term U.S. Treasury yields surged to their highest levels in over two decades due to ongoing tensions between the U.S. and Iran, with the 30-year yield nearing 5.322% and the 10-year yield at 4.736%. Rising geopolitical risks, including Iran's re...
World Liberty Financial (WLFI), backed by the Trump family, is financially supporting WorldClaw, a Hong Kong AI platform using Chinese AI models flagged by the US Pentagon for military ties. WLFI's USD1 stablecoin is used for payments on WorldClaw, c...
